NCT00053482Phase 2Completed

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2003-04Actual

Enrollment · participants357Actual

Source updated2024-03-18Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied: Smallpox
Treatments or interventions studied: type: BIOLOGICAL; name: ACAM2000 Smallpox Vaccine; type: BIOLOGICAL; name: Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®; otherNames: Dryvax®
Primary outcomes · main study measures: Read the study measures
measure: The Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine; description: The neutralizing antibody response titers were determined by the Plaque-Reduction Neutralization Test (PRNT50); timeFrame: Day 30 post-vaccination; measure: Participants With ≥ 4-fold Increase in Plaque-Reduction Neutralization Test (PRNT50) Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.; timeFrame: Day 30 post-vaccination; measure: Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine; timeFrame: Days 0 to 30 post-vaccination
History coverage: Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history